Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications
Open accessThe DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index.
Abstract
Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic, and viral infections. The severe acute respiratory syndrome (SARS)-CoV-2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with type 2 diabetes (T2D). Two coronavirus receptor proteins, angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here, we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“however, just like for ACE inhibitors, there is currently insufficient scientific evidence to judge whether use of DPP4 inhibitors impacts adversely on type 2 diabetes patients with COVID-19 (28).”
From ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency (2020) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“The results of several large studies examining the cardiovascular safety of GLP-1R agonists did not reveal imbalances in rates of inflammatory disorders or severe infections (113) (114) (115) (116) .”
ResultSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“The results of several large studies examining the cardiovascular safety of GLP-1R agonists did not reveal imbalances in rates of inflammatory disorders or severe infections (113) (114) (115) (116) .”
ResultHamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676 · cited 9×
“1), and generates vasodilatory Ang (1-7), collectively modulating often opposing actions of Ang II and ACE through Ang and angiotensin (1-7) receptors.”
BackgroundInfluentialGrasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469 · cited 2×
“form ACE2(1-740), however the biological importance of sACE2 remains uncertain.”
BackgroundCase-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy
Onder, G., Rezza, G., & Brusaferro, S. (2020) · JAMA · doi:10.1001/jama.2020.4683 · Cited by 4,171
Comorbidity and its impact on 1590 patients with covid-19 in China: a nationwide analysis
Guan, W.-J., Liang, W.-H., Zhao, Y., Liang, H.-R., Chen, Z.-S., Li, Y.-M., Liu, X.-Q., Chen, R.-C., Tang, C.-L., Wang, T., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00547-2020 · Cited by 3,680
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 2×
“Consistent with these findings, results of large trials examining the safety of saxagliptin, alogliptin, sitagliptin, and linagliptin in humans with T2D at risk for cardiovascular or renal disease did not reveal clinically relevant safety concerns related to infections, immune or inflammatory disorders (96-100).”
BackgroundResultGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., Francois, F., & Horwitz, L. I. (2020) · BMJ · doi:10.1136/bmj.m1966 · Cited by 3,054
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726 · cited 2×
“infectious diseases contribute to excess mortality in individuals with diabetes (25).”
BackgroundEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 2×
“Consistent with these findings, results of large trials examining the safety of saxagliptin, alogliptin, sitagliptin, and linagliptin in humans with T2D at risk for cardiovascular or renal disease did not reveal clinically relevant safety concerns related to infections, immune or inflammatory disorders (96-100).”
BackgroundResultAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 2×
“GLP-1R agonists exert broad anti-inflammatory actions in animals with experimental inflammation, and reduce biomarkers of systemic inflammation in human subjects with T2D and in people with obesity (105).”
BackgroundSelf-citationEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M., Leopoldi, A., Garreta, E., Hurtado del Pozo, C., Prosper, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.004 · Cited by 2,122 · cited 2×
“The extracellular domain of both ACE2 and sACE2 bind SARS-CoV (55), and SARS-CoV-2 (56), raising the possibility of exploring pharmacological administration of recombinant sACE2 as a therapeutic approach to sequester and block coronavirus cellular entry (57).”
BackgroundRenin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Simonnet, A., Chetboun, M., Poissy, J., Raverdy, V., Noulette, J., Duhamel, A., Labreuche, J., Mathieu, D., Pattou, F., Jourdain, M., et al. (2020) · Obesity · doi:10.1002/oby.22831 · Cited by 2,079
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061 · cited 2×
“As described for DPP4, the membrane-tethered ACE2 enzyme can be cleaved to yield a soluble circulating form ACE2(1-740); however, the biological importance of soluble ACE2 (sACE2) remains uncertain.”
BackgroundA Human Homolog of Angiotensin-converting Enzyme
Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G., & Turner, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002615200 · Cited by 2,009
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.-C., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020) · Circulation Research · doi:10.1161/circresaha.120.317015 · Cited by 1,882
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Assiri, A., Al-Tawfiq, J. A., Al-Rabeeah, A. A., Al-Rabiah, F. A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W. N., Balkhy, H. H., Al-Hakeem, R. F., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70204-4 · Cited by 1,435 · cited 4×
“As described for DPP4, the membrane-tethered ACE2 enzyme can be cleaved to yield a soluble circulating form ACE2(1-740); however, the biological importance of soluble ACE2 (sACE2) remains uncertain.”
BackgroundInfluentialClinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area
Booth, C. M. (2003) · JAMA · doi:10.1001/jama.289.21.joc30885 · Cited by 1,406
Diabetes is a risk factor for the progression and prognosis of COVID‐19
Guo, W., Li, M., Dong, Y., Zhou, H., Zhang, Z., Tian, C., Qin, R., Wang, H., Shen, Y., Du, K., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3319 · Cited by 1,404 · cited 3×
“As described for DPP4, the membrane-tethered ACE2 enzyme can be cleaved to yield a soluble circulating form ACE2(1-740); however, the biological importance of soluble ACE2 (sACE2) remains uncertain.”
BackgroundResultCDC COVID-19 Response Team, CDC COVID-19 Response Team, Chow, N., Fleming-Dutra, K., Gierke, R., Hall, A., Hughes, M., Pilishvili, T., Ritchey, M., Roguski, K., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6913e2 · Cited by 1,404
Jin, X., Lian, J.-S., Hu, J.-H., Gao, J., Zheng, L., Zhang, Y.-M., Hao, S.-R., Jia, H.-Y., Cai, H., Zhang, X.-L., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320926 · Cited by 1,385
Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission
Lighter, J., Phillips, M., Hochman, S., Sterling, S., Johnson, D., Francois, F., & Stachel, A. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa415 · Cited by 1,225
Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes
Yang, J.-K., Lin, S.-S., Ji, X.-J., & Guo, L.-M. (2010) · Acta Diabetologica · doi:10.1007/s00592-009-0109-4 · Cited by 1,084
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084 · cited 2×
“As described for DPP4, the membrane-tethered ACE2 enzyme can be cleaved to yield a soluble circulating form ACE2(1-740); however, the biological importance of soluble ACE2 (sACE2) remains uncertain.”
BackgroundResultGastrointestinal symptoms of 95 cases with SARS-CoV-2 infection
Lin, L., Jiang, X., Zhang, Z., Huang, S., Zhang, Z., Fang, Z., Gu, Z., Gao, L., Shi, H., Mai, L., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-321013 · Cited by 924
Heurich, A., Hofmann-Winkler, H., Gierer, S., Liepold, T., Jahn, O., & Pöhlmann, S. (2014) · Journal of Virology · doi:10.1128/jvi.02202-13 · Cited by 881
COVID-19, ACE2, and the cardiovascular consequences
South, A. M., Diz, D. I., & Chappell, M. C. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00217.2020 · Cited by 762
Metformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733 · cited 2×
“As described for DPP4, the membrane-tethered ACE2 enzyme can be cleaved to yield a soluble circulating form ACE2(1-740); however, the biological importance of soluble ACE2 (sACE2) remains uncertain.”
BackgroundACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection
Liu, F., Long, X., Zhang, B., Zhang, W., Chen, X., & Zhang, Z. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.04.040 · Cited by 718
Anti-inflammatory effects of metformin irrespective of diabetes status
Cameron, A. R., Morrison, V. L., Levin, D., Mohan, M., Forteath, C., Beall, C., McNeilly, A. D., Balfour, D. J. K., Savinko, T., Wong, A. K. F., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308445 · Cited by 704
Iwata-Yoshikawa, N., Okamura, T., Shimizu, Y., Hasegawa, H., Takeda, M., & Nagata, N. (2019) · Journal of Virology · doi:10.1128/jvi.01815-18 · Cited by 618
Rosenstock, J., Kahn, S. E., Johansen, O. E., Zinman, B., Espeland, M. A., Woerle, H. J., Pfarr, E., Keller, A., Mattheus, M., Baanstra, D., et al. (2019) · JAMA · doi:10.1001/jama.2019.13772 · Cited by 612
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609
Self-citationPrevalence and impact of diabetes among people infected with SARS-CoV-2
Fadini, G. P., Morieri, M. L., Longato, E., & Avogaro, A. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01236-2 · Cited by 549
Hansen, T. K., Thiel, S., Wouters, P. J., Christiansen, J. S., & Van den Berghe, G. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021478 · Cited by 499
Guo, J., Huang, Z., Lin, L., & Lv, J. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016219 · Cited by 464
Li, K., Wohlford-Lenane, C., Perlman, S., Zhao, J., Jewell, A. K., Reznikov, L. R., Gibson-Corley, K. N., Meyerholz, D. K., & McCray, P. B. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv499 · Cited by 459 · cited 2×
“Similarly, transgenic mice engineered to express human DPP4 become susceptible to lethal coronavirus infection with MERS-CoV (81).”
BackgroundPancreatic Injury Patterns in Patients With Coronavirus Disease 19 Pneumonia
Wang, F., Wang, H., Fan, J., Zhang, Y., Wang, H., & Zhao, Q. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.055 · Cited by 459
Shirato, K., Kawase, M., & Matsuyama, S. (2013) · Journal of Virology · doi:10.1128/jvi.01890-13 · Cited by 453
Petrilli, C. M., Jones, S., Yang, J., et al. (2020) · medRxiv · doi:10.1101/2020.04.08.20057794 · Cited by 435
Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F. F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 426
Zhou, J., Li, C., Zhao, G., Chu, H., Wang, D., Yan, H. H.-N., Poon, V. K.-M., Wen, L., Wong, B. H.-Y., Zhao, X., et al. (2017) · Science Advances · doi:10.1126/sciadv.aao4966 · Cited by 376
Kulcsar, K. A., Coleman, C. M., Beck, S. E., & Frieman, M. B. (2019) · JCI Insight · doi:10.1172/jci.insight.131774 · Cited by 373
Hodgson, K., Morris, J., Bridson, T., Govan, B., Rush, C., & Ketheesan, N. (2015) · Immunology · doi:10.1111/imm.12394 · Cited by 367
Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China
Xie, J., Tong, Z., Guan, X., Du, B., & Qiu, H. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.5619 · Cited by 348
Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors
Vuille-dit-Bille, R. N., Camargo, S. M., Emmenegger, L., Sasse, T., Kummer, E., Jando, J., Hamie, Q. M., Meier, C. F., Hunziker, S., Forras-Kaufmann, Z., et al. (2015) · Amino Acids · doi:10.1007/s00726-014-1889-6 · Cited by 312
Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy
Oudit, G. Y., Liu, G. C., Zhong, J., Basu, R., Chow, F. L., Zhou, J., Loibner, H., Janzek, E., Schuster, M., Penninger, J. M., et al. (2010) · Diabetes · doi:10.2337/db09-1218 · Cited by 300
Diabetes and the Severity of Pandemic Influenza A (H1N1) Infection
Allard, R., Leclerc, P., Tremblay, C., & Tannenbaum, T.-N. (2010) · Diabetes Care · doi:10.2337/dc09-2215 · Cited by 297
Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance
Ghorpade, D. S., Ozcan, L., Zheng, Z., Nicoloro, S. M., Shen, Y., Chen, E., Blüher, M., Czech, M. P., & Tabas, I. (2018) · Nature · doi:10.1038/nature26138 · Cited by 292
Insulin Receptor-Mediated Stimulation Boosts T Cell Immunity during Inflammation and Infection
Tsai, S., Clemente-Casares, X., Zhou, A. C., Lei, H., Ahn, J. J., Chan, Y. T., Choi, O., Luck, H., Woo, M., Dunn, S. E., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.003 · Cited by 272 · cited 2×
“Intriguingly, selective loss of insulin action in murine immune cells has been shown to attenuate the anti-inflammatory T-cell response to experimental influenza infection (123).”
BackgroundBergman, A. J., Stevens, C., Zhou, Y., Yi, B., Laethem, M., De Smet, M., Snyder, K., Hilliard, D., Tanaka, W., Zeng, W., et al. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.01.015 · Cited by 265
Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion
Lebrun, L. J., Lenaerts, K., Kiers, D., Pais de Barros, J.-P., Le Guern, N., Plesnik, J., Thomas, C., Bourgeois, T., Dejong, C. H. C., Kox, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.008 · Cited by 238 · cited 2×
“As described for DPP4, the membrane-tethered ACE2 enzyme can be cleaved to yield a soluble circulating form ACE2(1-740); however, the biological importance of soluble ACE2 (sACE2) remains uncertain.”
BackgroundSelf-citationThomas, M. C., Pickering, R. J., Tsorotes, D., Koitka, A., Sheehy, K., Bernardi, S., Toffoli, B., Nguyen-Huu, T.-P., Head, G. A., Fu, Y., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.219279 · Cited by 232
Tang, X.-C., Agnihothram, S. S., Jiao, Y., Stanhope, J., Graham, R. L., Peterson, E. C., Avnir, Y., Tallarico, A. S. C., Sheehan, J., Zhu, Q., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402074111 · Cited by 232 · cited 2×
“form ACE2(1-740), however the biological importance of sACE2 remains uncertain.”
BackgroundPascal, K. E., Coleman, C. M., Mujica, A. O., Kamat, V., Badithe, A., Fairhurst, J., Hunt, C., Strein, J., Berrebi, A., Sisk, J. M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510830112 · Cited by 217
Kahles, F., Meyer, C., Möllmann, J., Diebold, S., Findeisen, H. M., Lebherz, C., Trautwein, C., Koch, A., Tacke, F., Marx, N., et al. (2014) · Diabetes · doi:10.2337/db14-0100 · Cited by 212
COVID 19 and the Patient with Obesity – The Editors Speak Out
Ryan, D. H., Ravussin, E., & Heymsfield, S. (2020) · Obesity · doi:10.1002/oby.22808 · Cited by 207
A mouse model for MERS coronavirus-induced acute respiratory distress syndrome
Cockrell, A. S., Yount, B. L., Scobey, T., Jensen, K., Douglas, M., Beall, A., Tang, X.-C., Marasco, W. A., Heise, M. T., & Baric, R. S. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.226 · Cited by 206
Bindom, S. M., Hans, C. P., Xia, H., Boulares, A. H., & Lazartigues, E. (2010) · Diabetes · doi:10.2337/db09-0782 · Cited by 196
Šestan, M., Marinović, S., Kavazović, I., Cekinović, Đ., Wueest, S., Turk Wensveen, T., Brizić, I., Jonjić, S., Konrad, D., Wensveen, F. M., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.05.005 · Cited by 189 · cited 2×
“Acute viral respiratory infection has been linked to the rapid development of transient insulin resistance, both in otherwise healthy euglycemic normal weight or overweight individuals (24).”
BackgroundDipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract
Meyerholz, D. K., Lambertz, A. M., & McCray, P. B. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.09.014 · Cited by 181
Romaní-Pérez, M., Outeiriño-Iglesias, V., Moya, C. M., Santisteban, P., González-Matías, L. C., Vigo, E., & Mallo, F. (2015) · Endocrinology · doi:10.1210/en.2014-1685 · Cited by 178
Raj, V. S., Smits, S. L., Provacia, L. B., van den Brand, J. M. A., Wiersma, L., Ouwendijk, W. J. D., Bestebroer, T. M., Spronken, M. I., van Amerongen, G., Rottier, P. J. M., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02935-13 · Cited by 173
Limburg, H., Harbig, A., Bestle, D., Stein, D. A., Moulton, H. M., Jaeger, J., Janga, H., Hardes, K., Koepke, J., Schulte, L., et al. (2019) · Journal of Virology · doi:10.1128/jvi.00649-19 · Cited by 170
SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells
Mossel, E. C., Wang, J., Jeffers, S., Edeen, K. E., Wang, S., Cosgrove, G. P., Funk, C. J., Manzer, R., Miura, T. A., Pearson, L. D., et al. (2008) · Virology · doi:10.1016/j.virol.2007.09.045 · Cited by 168
Gooßen, K., & Gräber, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01610.x · Cited by 167
Gut-Brain Glucose Signaling in Energy Homeostasis
Soty, M., Gautier-Stein, A., Rajas, F., & Mithieux, G. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.032 · Cited by 163
The global diabetes epidemic: what does it mean for infectious diseases in tropical countries?
van Crevel, R., van de Vijver, S., & Moore, D. A. J. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30081-x · Cited by 158
Alqahtani, F. Y., Aleanizy, F. S., Ali El Hadi Mohamed, R., Alanazi, M. S., Mohamed, N., Alrasheed, M. M., Abanmy, N., & Alhawassi, T. (2019) · Epidemiology and Infection · doi:10.1017/s0950268818002923 · Cited by 147
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
(2015) · New England Journal of Medicine · doi:10.1056/nejmx150029 · Cited by 147
Varin, E. M., Mulvihill, E. E., Beaudry, J. L., Pujadas, G., Fuchs, S., Tanti, J.-F., Fazio, S., Kaur, K., Cao, X., Baggio, L. L., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.001 · Cited by 138
Self-citationViby, N.-E., Isidor, M. S., Buggeskov, K. B., Poulsen, S. S., Hansen, J. B., & Kissow, H. (2013) · Endocrinology · doi:10.1210/en.2013-1666 · Cited by 133
Hamblin, P. S., Wong, R., Ekinci, E. I., Fourlanos, S., Shah, S., Jones, A. R., Hare, M. J. L., Calder, G. L., Epa, D. S., George, E. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00139 · Cited by 126 · cited 2×
“Accordingly, the available evidence suggests reevaluation of or discontinuation of these agents in very unwell ambulatory individuals, and the SGLT2 inhibitors should be routinely discontinued in unstable patients with severe SARS-CoV-2 infection upon admission to hospital (125).”
BackgroundGarbati, M. A., Fagbo, S. F., Fang, V. J., Skakni, L. I., Joseph, M. V., Wani, T. A., Cowling, B. J., Peiris, M. J. S., & Hakawi, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165978 · Cited by 111
Loss of ACE2 Exaggerates High-Calorie Diet–Induced Insulin Resistance by Reduction of GLUT4 in Mice
Takeda, M., Yamamoto, K., Takemura, Y., Takeshita, H., Hongyo, K., Kawai, T., Hanasaki-Yamamoto, H., Oguro, R., Takami, Y., Tatara, Y., et al. (2013) · Diabetes · doi:10.2337/db12-0177 · Cited by 110
Seys, L., Widagdo, W., Verhamme, F. M., KleinJan, A., Janssens, W., Joos, G., Bracke, K. R., Haagmans, B. L., & Brusselle, G. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix741 · Cited by 105
Toki, S., Goleniewska, K., Reiss, S., Zhang, J., Bloodworth, M. H., Stier, M. T., Zhou, W., Newcomb, D. C., Ware, L. B., Stanwood, G. D., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.043 · Cited by 104
Mulvihill, E. E., Varin, E. M., Gladanac, B., Campbell, J. E., Ussher, J. R., Baggio, L. L., Yusta, B., Ayala, J., Burmeister, M. A., Matthews, D., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.007 · Cited by 102 · cited 2×
“form ACE2(1-740), however the biological importance of sACE2 remains uncertain.”
BackgroundSelf-citationCockrell, A. S., Peck, K. M., Yount, B. L., Agnihothram, S. S., Scobey, T., Curnes, N. R., Baric, R. S., & Heise, M. T. (2014) · Journal of Virology · doi:10.1128/jvi.03764-13 · Cited by 97
Kleine-Weber, H., Schroeder, S., Krüger, N., Prokscha, A., Naim, H. Y., Müller, M. A., Drosten, C., Pöhlmann, S., & Hoffmann, M. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1713705 · Cited by 97
Highly ACE2 Expression in Pancreas May Cause Pancreas Damage After SARS-CoV-2 InfectionPreprint
Liu, F., Long, X., Zou, W., et al. (2020) · medRxiv · doi:10.1101/2020.02.28.20029181 · Cited by 94
Basu, A., Veettil, S., Dyer, R., Peyser, T., & Basu, R. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0410 · Cited by 93
Kim, Y., Cheon, S., Min, C.-K., Sohn, K. M., Kang, Y. J., Cha, Y.-J., Kang, J.-I., Han, S. K., Ha, N.-Y., Kim, G., et al. (2016) · mBio · doi:10.1128/mbio.00019-16 · Cited by 92
Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice
Zhou, F., Zhang, Y., Chen, J., Hu, X., & Xu, Y. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.10.016 · Cited by 91
Badawi, A., & Ryoo, S. G. (2016) · Journal of Public Health Research · doi:10.4081/jphr.2016.733 · Cited by 91
Fayfman, M., Galindo, R. J., Rubin, D. J., Mize, D. L., Anzola, I., Urrutia, M. A., Ramos, C., Pasquel, F. J., Haw, J. S., Vellanki, P., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1760 · Cited by 85 · cited 2×
“Similarly, twicedaily exenatide appears safe and effective when used alone or in combination with basal insulin for blood glucose management in noncritically ill hospitalized patients with T2D treated on general medicine or surgery wards (118).”
BackgroundZhang, L., Pang, X.-F., Bai, F., Wang, N.-P., Shah, A., McKallip, R. J., Li, X., Wang, X., & Zhao, Z. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6592-7 · Cited by 84
Increased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2 diabetes
Gutta, S., Grobe, N., Kumbaji, M., Osman, H., Saklayen, M. G., Li, G., & Elased, K. M. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00565.2017 · Cited by 75
Hulst, A. H., Visscher, M. J., Godfried, M. B., Thiel, B., Gerritse, B. M., Scohy, T. V., Bouwman, R. A., Willemsen, M. G. A., Hollmann, M. W., Preckel, B., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13927 · Cited by 75 · cited 2×
“Liraglutide has been shown to be safe and effective when used for acute perioperative control of blood glucose in adult human subjects undergoing elective cardiovascular surgery (117).”
BackgroundACE2 deficiency reduces β-cell mass and impairs β-cell proliferation in obese C57BL/6 mice
Shoemaker, R., Yiannikouris, F., Thatcher, S., & Cassis, L. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00054.2015 · Cited by 69
van Vught, L. A., Scicluna, B. P., Hoogendijk, A. J., Wiewel, M. A., Klouwenberg, P. M. C. K., Cremer, O. L., Horn, J., Nürnberg, P., Bonten, M. J. M., Schultz, M. J., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1429-8 · Cited by 69
Peck, K. M., Cockrell, A. S., Yount, B. L., Scobey, T., Baric, R. S., & Heise, M. T. (2015) · Journal of Virology · doi:10.1128/jvi.03445-14 · Cited by 68
GLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease
Lebherz, C., Schlieper, G., Möllmann, J., Kahles, F., Schwarz, M., Brünsing, J., Dimkovic, N., Koch, A., Trautwein, C., Flöge, J., et al. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.03.010 · Cited by 65 · cited 2×
“As described for DPP4, the membrane-tethered ACE2 enzyme can be cleaved to yield a soluble circulating form ACE2(1-740); however, the biological importance of soluble ACE2 (sACE2) remains uncertain.”
BackgroundSystematic review of incretin therapy during peri-operative and intensive care
Hulst, A. H., Plummer, M. P., Hollmann, M. W., DeVries, J. H., Preckel, B., Deane, A. M., & Hermanides, J. (2018) · Critical Care · doi:10.1186/s13054-018-2197-4 · Cited by 63
Pasquel, F. J., Fayfman, M., & Umpierrez, G. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1184-8 · Cited by 61
Bloodworth, M. H., Rusznak, M., Pfister, C. C., Zhang, J., Bastarache, L., Calvillo, S. A., Chappell, J. D., Boyd, K. L., Toki, S., Newcomb, D. C., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.01.053 · Cited by 57
Wong, T. P., Ho, K. Y., Ng, E. K., Debnam, E. S., & Leung, P. S. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00562.2011 · Cited by 50
Vora, K. A., Porter, G., Peng, R., Cui, Y., Pryor, K., Eiermann, G., & Zaller, D. M. (2009) · BMC Immunology · doi:10.1186/1471-2172-10-19 · Cited by 49
Caì, Y., Yú, S., Postnikova, E. N., Mazur, S., Bernbaum, J. G., Burk, R., Zhāng, T., Radoshitzky, S. R., Müller, M. A., Jordan, I., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112060 · Cited by 48
939: LIRAGLUTIDE ATTENUATES LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY IN MICE
Zhang, Y., Li, J., & Peng, Z. (2016) · Critical Care Medicine · doi:10.1097/01.ccm.0000509615.06302.57 · Cited by 48
Weinrauch, L. A., D’Elia, J. A., Weir, M. R., Bunnapradist, S., Finn, P. V., Liu, J., Claggett, B. L., & Monaco, A. P. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.08.038 · Cited by 47
Saenwongsa, W., Nithichanon, A., Chittaganpitch, M., Buayai, K., Kewcharoenwong, C., Thumrongwilainet, B., Butta, P., Palaga, T., Takahashi, Y., Ato, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60213-0 · Cited by 46
Immune response to influenza vaccination in the elderly is altered by chronic medication use
Agarwal, D., Schmader, K. E., Kossenkov, A. V., Doyle, S. A., Kurupati, R. K., & Ertl, H. C. J. (2018) · Immunity & Ageing · doi:10.1186/s12979-018-0124-9 · Cited by 44
Modulation of Hematopoietic Chemokine Effects In Vitro and In Vivo by DPP-4/CD26
Broxmeyer, H. E., Capitano, M. L., Campbell, T., Hangoc, G., & Cooper, S. H. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0026 · Cited by 43
Andrieu, T., Thibault, V., Malet, I., Laporte, J. M., Bauvois, B., Agut, H., & Cahour, A. (2003) · Journal of Clinical Virology · doi:10.1016/s1386-6532(02)00128-2 · Cited by 42
Best, C., Struthers, H., Laciny, E., Royal, M., Reeds, D. N., & Yarasheski, K. E. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1531 · Cited by 40
Burns, K. D., Lytvyn, Y., Mahmud, F. H., Daneman, D., Deda, L., Dunger, D. B., Deanfield, J. E., Dalton, R. N., Elia, Y. T., Har, R. L. H., et al. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00438.2016 · Cited by 40
Lu, M., Zuo, Y.-Y., Guo, J., Wen, X., & Kang, Y. M. (2018) · Medicine · doi:10.1097/md.0000000000012138 · Cited by 40
Goodwin, S. R., Reeds, D. N., Royal, M., Struthers, H., Laciny, E., & Yarasheski, K. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3532 · Cited by 38
Inn, K., Kim, Y., Aigerim, A., Park, U., Hwang, E., Choi, M., Ys, K., & Cho, N. (2018) · Virology · doi:10.1016/j.virol.2018.03.015 · Cited by 37
Price, J. D., Linder, G., Li, W., Zimmermann, B., Rother, K. I., Malek, R., Alattar, M., & Tarbell, K. V. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12144 · Cited by 36
Šromová, L., Bušek, P., Posová, H., Potočková, J., Škrha, P., Anděl, M., & Šedo, A. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.06.020 · Cited by 36
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
Examine Investigators (2014) · Aston Publications Explorer (Aston University) · Cited by 36
Urinary Angiotensin Converting Enzyme 2 Increases in Patients With Type 2 Diabetic Mellitus
Liang, Y., Deng, H., Bi, S., Cui, Z., Lata, A., Zheng, D., & Wang, Y. (2015) · Kidney & Blood Pressure Research · doi:10.1159/000368486 · Cited by 34
Algaissi, A. A., Agrawal, A. S., Han, S., Peng, B., Luo, C., Li, F., Chan, T., Couch, R. B., & Tseng, C.-T. K. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy574 · Cited by 30
Dubé, M. P., Chan, E. S., Lake, J. E., Williams, B., Kinslow, J. D., LANDAY, A. L., Coombs, R. W., Floris-Moore, M., Ribaudo, H. J., & Yarasheski, K. E. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1051 · Cited by 30
Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study
van der Zanden, R., de Vries, F., Lalmohamed, A., Driessen, J. H. M., de Boer, A., Rohde, G. G. U., Neef, C., & den Heijer, C. D. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139367 · Cited by 27
Garrouste-Orgeas, M., Azoulay, É., Ruckly, S., Schwebel, C., de Montmollin, É., Bédos, J., Souweine, B., Marcotte, G., Adrie, C., Goldgran-Tolédano, D., et al. (2018) · Infection · doi:10.1007/s15010-018-1169-6 · Cited by 24
Lee, M. Y., Fraser, J. D., Chapman, M. J., Sundararajan, K., Umapathysivam, M. M., Summers, M. J., Zaknic, A. V., Rayner, C. K., Meier, J. J., Horowitz, M., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0307 · Cited by 23
Ploquin, M. J.-Y., Casrouge, A., Madec, Y., Noël, N., Jacquelin, B., Huot, N., Duffy, D., Jochems, S. P., Micci, L., Lécuroux, C., et al. (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25144 · Cited by 19
Ikeda, Y., Ito, H., & Hashimoto, K. (1999) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(98)00016-6 · Cited by 18
van Poppel, P. C. M., Gresnigt, M. S., Smits, P., Netea, M. G., & Tack, C. J. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.039 · Cited by 17
Research works printed but not linked: 1
- Audit I. ICNARC Report on COVID-19 in Critical Care. In. April 10 2020 ed: London, UK: Intensive Care National Audit & Research Centre (ICNARC); 2020. https:// www.icnarc.org/About/Latest-News/2020/04/04/ Report-On-2249-Patients-Critically-Ill-With-Covid-19
Cited by
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Cariou, B., Hadjadj, S., Wargny, M., Pichelin, M., Al-Salameh, A., Allix, I., Amadou, C., Arnault, G., Baudoux, F., Bauduceau, B., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05180-x · Cited by 813
Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis
Kumar, A., Arora, A., Sharma, P., Anikhindi, S. A., Bansal, N., Singla, V., Khare, S., & Srivastava, A. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.04.044 · Cited by 776
Obesity ‑ a risk factor for increased COVID‑19 prevalence, severity and lethality (Review)
Petrakis, D., Margină, D., Tsarouhas, K., Tekos, F., Stan, M., Nikitovic, D., Kouretas, D., Spandidos, D., & Tsatsakis, A. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11127 · Cited by 388
Diabetes, infection risk and COVID-19
Erener, S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101044 · Cited by 351
Metadata
- Authors
- Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J
- ORCID
- Drucker, Daniel J
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-04-15
- Volume
- 41
- Issue
- 3
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7184382
- OpenAlex
- W3015989800
- Cited by
- 399
- References
- 132
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 13 · 2023: 37 · 2022: 72 · 2021: 100 · 2020: 162
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk Fonden (NNF19SA0035502)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- type 2 diabetes, COVID-19 pandemic, SARS-CoV-2, ACE2, dipeptidyl peptidase IV, DPP-4 inhibitors, glucose-lowering agents, immunomodulation, glucose homeostasis, inflammation
- MeSH terms
- Betacoronavirus, Receptors, Coronavirus, Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, Animals, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Insulin, Peptidyl-Dipeptidase A, Lung, Obesity, Pneumonia, Viral, Receptors, Virus, Risk Factors, Serine Endopeptidases, Coronavirus Infections, Dipeptidyl Peptidase 4, Gastrointestinal Tract, Dipeptidyl-Peptidase IV Inhibitors, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.